Study confirms target of potent chronic leukemia drug

A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia.

In clinical trials, ibrutinib has often shown exceptional activity in people with (CLL). The agent targets a molecule called Bruton's tyrosine kinase (BTK). It permanently incapacitates the molecule, and this stops the transmission of an important signal that promotes cell growth and proliferation.

But ibrutinib also inhibits other molecules in CLL cells. Like BTK, these molecules are proteins called kinases, and they might be important for CLL-cell survival, the researchers say.

"Ibrutinib's lack of selectivity might mean that BTK is not the critical target in CLL, and that future drugs developed for CLL should focus on other molecules," says principal investigator Amy Johnson, PhD, associate professor of medicine in the division of hematology, and an OSUCCC – James researcher. However, the findings, published in the journal Blood, validated BTK inhibition.

"This study shows that BTK is an important therapeutic target in CLL," says first author Jennifer Woyach, MD, assistant professor in the division of hematology and an OSUCCC – James researcher. "Inactivating BTK alone delayed CLL development in a mouse model, confirming that BTK is a clinically important target in CLL. This suggests that development of selective BTK inhibitors – in addition to multi-kinase inhibitors like ibrutinib – is reasonable in CLL."

To investigate the role of BTK in CLL, Johnson, Woyach and their colleagues used CLL cells from patients and two CLL mouse models, one of which spontaneously develops a malignancy very similar to human CLL. The researchers blocked BTK activity two ways: genetically and pharmacologically, using ibrutinib.

Key findings included:

  • Inhibiting BTK expression in human CLL cells significantly decreased survival in tumor cells from 31 patients;
  • A mouse model with inactive BTK due to a point mutation survived significantly longer than mice with active BTK (18.3 versus 13.2 months, respectively);
  • In a mouse model of spontaneous CLL, animals treated with ibrutinib survived significantly longer than controls from the time of diagnosis (46 versus 24 days, respectively);
  • In the same , treatment with ibrutinib significantly delayed leukemia onset compared with controls (10.7 versus 7.0 months) and extended overall survival (14.5 versus 12.3 months, respectively).

"Overall," Johnson says, "our findings validate BTK as a target for CLL therapy and strongly suggest that selective kinase-inhibitors might work in CLL like the drug imatinib does in chronic myeloid leukemia."

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

Nov 27, 2014

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.